OnKure Therapeutics Inc.

5.75
-0.27 (-4.49%)
At close: Feb 06, 2025, 2:52 PM
undefined%
Bid 5.63
Market Cap 72.75M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) 0.08
PE Ratio (ttm) 71.88
Forward PE n/a
Analyst Buy
Ask 5.82
Volume 16,748
Avg. Volume (20D) 116,311
Open 6.10
Previous Close 6.02
Day's Range 5.70 - 6.30
52-Week Range 4.58 - 20.00
Beta undefined

About OKUR

OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado....

Industry Biotechnology
Sector Healthcare
IPO Date n/a
Employees 50
Stock Exchange NASDAQ
Ticker Symbol OKUR

Analyst Forecast

According to 4 analyst ratings, the average rating for OKUR stock is "Buy." The 12-month stock price forecast is $34, which is an increase of 491.30% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts